Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis

Ticker
ANEB

Price
0.48
Stock movement down
-0.01 (-1.21%)
Company name
Anebulo Pharmaceuticals Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
19.71M
Ent value
10.32M
Price/Sales
-
Price/Book
2.02
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-35.35%
1 year return (CAGR)
-66.90%
3 year return (CAGR)
-45.95%
5 year return (CAGR)
-
10 year return (CAGR)
-
Last updated: 2026-02-19

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

ANEB does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book2.02
EV to Sales-

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

FINANCIALS

Per share

Loading...
Per share data
Current share count40.78M
EPS (TTM)-0.21
FCF per share (TTM)-0.14

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-9.07M
Net income (TTM)-8.44M
EPS (TTM)-0.21
EPS (1y forward)-0.46

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash10.35M
Net receivables0.00
Total current assets10.54M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment0.00
Total assets10.70M
Accounts payable607.54K
Short/Current long term debt0.00
Total current liabilities607.54K
Total liabilities963.82K
Shareholder's equity9.74M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-5.93M
Capital expenditures (TTM)4.00
Free cash flow (TTM)-5.93M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-86.70%
Return on Assets-78.89%
Return on Invested Capital-86.70%
Cash Return on Invested Capital-60.93%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open0.48
Daily high0.51
Daily low0.46
Daily Volume65K
All-time high8.95
1y analyst estimate3.00
Beta-0.81
EPS (TTM)-0.21
Dividend per share0.00
Ex-div date-
Next earnings date7 May 2026

Downside potential

Loading...
Downside potential data
ANEBS&P500
Current price drop from All-time high-94.63%-1.82%
Highest price drop-94.70%-56.47%
Date of highest drop11 Feb 20269 Mar 2009
Avg drop from high-63.28%-10.84%
Avg time to new high241 days12 days
Max time to new high1192 days1805 days

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
ANEB (Anebulo Pharmaceuticals Inc) company logo
Marketcap
19.71M
Marketcap category
Small-cap
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. The company's lead product candidate is the selonabant, a small-molecule antagonist of cannabinoid binding receptor type-1(CB1), which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. Anebulo Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Lakeway, Texas.
Employees
2
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...